Header Logo

Connection

ELENI EFSTATHIOU to Treatment Outcome

Back to Details
This is a "connection" page, showing publications ELENI EFSTATHIOU has written about Treatment Outcome.
ELENI EFSTATHIOU
Connection Strength
0.368
Treatment Outcome
  1. Niraparib plus abiraterone acetate with prednisone in patients with?metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the?randomized phase III MAGNITUDE trial. Ann Oncol. 2023 09; 34(9):772-782.
    View in: PubMed
    Score: 0.050
  2. An evaluation of apalutamide for the treatment of prostate cancer. Expert Opin Pharmacother. 2020 Sep; 21(13):1537-1546.
    View in: PubMed
    Score: 0.040
  3. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5.
    View in: PubMed
    Score: 0.040
  4. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Int J Surg Oncol. 2014; 2014:987475.
    View in: PubMed
    Score: 0.026
  5. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res. 2007 Jan-Feb; 27(1B):611-7.
    View in: PubMed
    Score: 0.016
  6. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology. 2005 Jan; 65(1):126-30.
    View in: PubMed
    Score: 0.014
  7. Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. J Urol. 2023 03; 209(3):532-539.
    View in: PubMed
    Score: 0.012
  8. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. Eur J Cancer. 2021 12; 159:237-246.
    View in: PubMed
    Score: 0.011
  9. Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. Eur J Cancer. 2020 01; 125:153-163.
    View in: PubMed
    Score: 0.010
  10. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Eur Urol Oncol. 2018 12; 1(6):467-475.
    View in: PubMed
    Score: 0.009
  11. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents. Clin Genitourin Cancer. 2018 08; 16(4):e777-e784.
    View in: PubMed
    Score: 0.009
  12. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93.
    View in: PubMed
    Score: 0.008
  13. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21.
    View in: PubMed
    Score: 0.007
  14. Targeting the interleukin-11 receptor a in metastatic prostate cancer: A first-in-man study. Cancer. 2015 Jul 15; 121(14):2411-21.
    View in: PubMed
    Score: 0.007
  15. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015 Mar; 16(3):338-48.
    View in: PubMed
    Score: 0.007
  16. Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol. 2015; 2015:610597.
    View in: PubMed
    Score: 0.007
  17. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 01; 33(7):723-31.
    View in: PubMed
    Score: 0.007
  18. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014 Aug; 15(9):e404-14.
    View in: PubMed
    Score: 0.007
  19. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014 Jun; 50(9):1617-27.
    View in: PubMed
    Score: 0.007
  20. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25.
    View in: PubMed
    Score: 0.006
  21. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013 Aug; 3(8):849-61.
    View in: PubMed
    Score: 0.006
  22. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61.
    View in: PubMed
    Score: 0.005
  23. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26; 364(21):1995-2005.
    View in: PubMed
    Score: 0.005
  24. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res. 2011 Apr; 31(4):1475-82.
    View in: PubMed
    Score: 0.005
  25. Recurrent seminomas: clinical features and biologic implications. Urol Oncol. 2012 Jul-Aug; 30(4):494-501.
    View in: PubMed
    Score: 0.005
  26. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010 Oct; 24(10):1769-78.
    View in: PubMed
    Score: 0.005
  27. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24; 375(9724):1437-46.
    View in: PubMed
    Score: 0.005
  28. Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res. 2006 Jul-Aug; 26(4B):3175-81.
    View in: PubMed
    Score: 0.004
  29. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol Oncol. 2005 Nov; 99(2):376-82.
    View in: PubMed
    Score: 0.004
  30. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer. 2005 Jun 15; 103(12):2629-35.
    View in: PubMed
    Score: 0.004
  31. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005 May; 97(2):436-41.
    View in: PubMed
    Score: 0.004
  32. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005 May; 16(5):773-9.
    View in: PubMed
    Score: 0.003
  33. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol. 2005 Feb; 16(2):307-13.
    View in: PubMed
    Score: 0.003
  34. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004 Sep; 64(3):479-84.
    View in: PubMed
    Score: 0.003
  35. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004; 5(2):112-7.
    View in: PubMed
    Score: 0.003
  36. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 2004; 66(2):112-7.
    View in: PubMed
    Score: 0.003
  37. Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology. 2002; 62(2):97-102.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.